Tirzepatide is a dual GIP and GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes. Administered as a weekly injection, it also promotes significant weight loss by reducing appetite and slowing digestion. Patients struggling with glycemic management or obesity-related conditions benefit most from this treatment.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends